

dorsaVi Ltd and controlled entities
ABN 15 129 742 408

HALF-YEAR INFORMATION
FOR THE SIX MONTHS ENDED 31 DECEMBER 2017
PROVIDED TO THE ASX UNDER LISTING RULE 4.2A.3

This half-year financial report is to be read in conjunction with the financial report for the year ended 30 June 2017.

Appendix 4D

Half-Year Report for the six months ended 31 December 2017

Name of entity: **dorsaVi Ltd and controlled entities**

ABN: 15 129 742 409

1. Reporting period

Report for the half-year ended: **31 December 2017**

Previous corresponding periods: Financial year ended 30 June 2017
Half-year ended 31 December 2016

2. Results for announcement to the market

Revenues from ordinary activities (<i>item 2.1</i>)	up	15%	to	2,239,089
Loss from ordinary activities after tax attributable to members (<i>item 2.2</i>)	up	56%	to	1,972,062
Loss for the period attributable to members (<i>item 2.3</i>)	up	56%	to	1,972,062
Dividends (<i>item 2.4</i>)	Amount per security		Franked amount per security	
Interim dividend	0¢		0¢	
Final dividend	0¢		0¢	
Previous corresponding period	0¢		0¢	
Record date for determining entitlements to the dividend (<i>item 2.5</i>)	N/A			
Brief explanation of any of the figures reported above necessary to enable the figures to be understood (<i>item 2.6</i>): N/A				

3. Net tangible assets per security (*item 3*)

	Current period	Previous corresponding period
Net tangible asset backing per ordinary security	0.05	0.06

4. Details of entities over which control has been gained or lost during the period: (item 4)

Control gained over entities

Name of entities (item 4.1)	N/A
Date(s) of gain of control (item 4.2)	N/A
Contribution to consolidated profit (loss) from ordinary activities after tax by the controlled entities since the date(s) in the current period on which control was acquired (item 4.3)	N/A
Profit (loss) from ordinary activities after tax of the controlled entities for the whole of the previous corresponding period (item 4.3)	N/A

Loss of control of entities

Name of entities (item 4.1)	N/A
Date(s) of loss of control (item 4.2)	N/A
Contribution to consolidated profit (loss) from ordinary activities after tax by the controlled entities to the date(s) in the current period when control was lost (item 4.3).	N/A
Profit (loss) from ordinary activities after tax of the controlled entities for the whole of the previous corresponding period (item 4.3)	N/A

5. Dividends (item 5)

	Date of payment	Total amount of dividend
Interim dividend year ended 30 June 2016	N/A	\$0
Final dividend year ended 30 June 2015	N/A	\$0

Amount per security

	Amount per security	Franked amount per security at % tax	Amount per security of foreign sourced dividend
Total dividend: Current year	0¢	0¢	0¢
Previous year	0¢	0¢	0¢

Total dividend on all securities

	Current period \$A'000	Previous corresponding Period - \$A'000
Ordinary securities <i>(each class separately)</i>	N/A	N/A
Preference securities <i>(each class separately)</i>		
Other equity instruments <i>(each class separately)</i>		
Total	N/A	N/A

6. Details of dividend or distribution reinvestment plans in operation are described below (item 6):

N/A

The last date(s) for receipt of election notices for participation in the dividend or distribution reinvestment plan

N/A

7. Details of associates and joint venture entities *(item 7)*

Name of associate or joint venture entity	%Securities held
N/A	N/A

Aggregate share of profits (losses) of associates and joint venture entities

Group's share of associates' and joint venture entities':	2017 \$	2016 \$
Profit (loss) from ordinary activities before tax	N/A	N/A
Income tax on ordinary activities		
Net profit (loss) from ordinary activities after tax	N/A	N/A
Adjustments		
Share of net profit (loss) of associates and joint venture entities	N/A	N/A

8. The financial information provided in the Appendix 4D is based on the half-year condensed financial report (attached).

9. Independent review of the financial report *(item 9)*

The financial report has been independently reviewed. The financial report is not subject to a qualified independent review statement.

**dorsaVi Ltd
and controlled entities
ABN: 15 129 742 409**

**FINANCIAL REPORT
FOR THE HALF-YEAR ENDED
31 DECEMBER 2017**

This half-year financial report is to
be read in conjunction with the
financial report for the year ended
30 June 2017

dorsaVi Ltd and controlled entities
FINANCIAL REPORT FOR THE HALF-YEAR ENDED
31 DECEMBER 2017

TABLE OF CONTENTS

	Page
Directors' Report	3
Auditor's Independence Declaration	6
Financial Report for the half-year ended 31 December 2017:	
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	7
Condensed Consolidated Statement of Financial Position	9
Condensed Consolidated Statement of Changes in Equity	10
Condensed Consolidated Statement of Cash Flows	11
Notes to the Condensed Consolidated Financial Statements	12
Directors' Declaration	21
Independent Auditor's Review Report	22

DIRECTORS' REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2017

The directors present their report together with the condensed financial report of the consolidated entity consisting of dorsaVi Ltd (the Company) and the entities it controlled (the Group), for the half-year ended 31 December 2017 and independent review report thereon.

Directors' names

The names of the directors in office at any time during or since the end of the half-year are:

Name	Period of directorship
Greg Tweedly (chairman)	Director since 29 October 2013
Ashraf Attia	Director since 14 July 2008
Michael Panaccio	Director since 16 May 2008
Caroline Elliott	Director since 24 November 2017
Andrew James Ronchi	Director since 18 February 2008
Herb Elliott	Retired 23 November 2017

Except as noted above the directors have been in office since the start of the financial period to the date of this report.

Review of operations

Revenue for the six months to December 2017 was \$2,239,089 (2016: \$1,953,606) driven by 12.8% growth in sales revenue to \$1,949,440 (2016: \$1,728,724).

The loss from continuing operations after income tax for the six months to December 2017 was \$1,972,062 as compared to \$1,263,208 for the six months to 31 December 2016. This increase reflects higher share-based payments (\$290,000), higher depreciation and amortisation (\$184,000) together with increased marketing and selling activities, in particular, in the United States (US).

The directors expect revenue to continue to grow year on year. Factors driving this growth include; the continued roll out of the global marketing plan, increasing sales from our team in the US, new product releases with major functional improvements and ongoing customer-focused software development.

The material business risks that are likely to have an effect on the financial prospects of the Group include:

- dorsaVi Ltd relies on its ability to enhance its movement monitoring intellectual property. A failure to meet future customer requirements would lead to a loss of opportunities and adversely impact operating results and the financial position of dorsaVi Ltd.
- Over time, dorsaVi Ltd may be subjected to increased competition if potential competitors develop new technologies or make scientific or systems advances that compare with or compete with dorsaVi Ltd's products.
- In the medical sector (but not the Elite Sports or OHS sectors), sales and adoption rates of dorsaVi Ltd's system are, in part, likely to be influenced by the availability and level of reimbursement from government and/or insurers. Whilst dorsaVi Ltd's products already benefit from reimbursement in some circumstances, there is no guarantee that the use of dorsaVi Ltd's products will receive further reimbursement.
- General economic conditions, movements in interest and inflation rates and currency exchange rates may have an adverse effect on dorsaVi Ltd's activities, as well as on its ability to fund those activities. In particular, much of its future income is expected to come from the US and European markets and therefore dorsaVi Ltd's activities will be affected by currency exchange fluctuations.

DIRECTORS' REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2017

- dorsaVi Ltd is not currently profitable. Proceeds from the capital raising in December 2016 and January 2017 were and are primarily being used to fund: the recruitment and signing of additional Organisational Health and Safety agents in the US; the development and launch of the new v6 product (myViSafe and ViMove 2); and to provide general working capital. There is no guarantee that the recruitment of agents and the rollout of v6 (myViSafe and ViMove 2) will result in profitability for the Company. If either the recruitment or rollout are lower or less successful than planned, dorsaVi may need to raise further capital in the future.

Cash and cash equivalents as at 31 December 2017 were \$6,749,478 (30 June 2017: \$8,609,602).

Significant changes in the state of affairs

The following changes in the state of affairs occurred during the period and to the date of this report:

- On 14 July 2017, dorsaVi Ltd received 510(k) clearance by the US Food and Drug Administration (FDA) for the next generation ViMove2 sensor designed to measure, record and analyse movement and muscle activity of the lower back.
- On 14 August 2017, dorsaVi Ltd issued 250,000 fully paid ordinary shares, at \$nil per share, to employees, under the dorsaVi ESOP. The issue of these shares arose on the vesting of 250,000 performance rights previously granted as a result of those employees meeting the performance conditions attached to the rights.
- On 6 October 2017, dorsaVi Ltd issued 321,113 fully paid ordinary shares, at \$nil per share, to employees, under the dorsaVi ESOP. The issue of these shares arose on the vesting of 321,113 performance rights previously granted as a result of those employees meeting the performance conditions attached to the rights. On the same day 257,887 performance rights and 78,333 options previously granted, lapsed.
- On 18 October 2017, dorsaVi Ltd announced that they had been awarded a Federal Government Advanced Manufacturing Growth Fund grant exceeding \$1.1m to assist in the development and implementation of advanced manufacturing activities over a twenty-eight-month period ending March 2020.
- On 25 October 2017, dorsaVi Ltd announced that Japara Healthcare (ASX: JHC), one of Australia's largest aged care providers, will implement dorsaVi's myViSafe to improve workplace manual handling safety for its staff.
- On 23 November 2017, Herb Elliott retired, effective immediately, as Chairman and Director of dorsaVi Ltd.
- On 23 November 2017, Greg Tweedly was appointed as Chairman of dorsaVi Ltd at dorsaVi Ltd's annual general meeting and retired as Chair of the Audit and Risk Committee.
- On 24 November 2017, dorsaVi Ltd appointed Caroline Elliott as Non-executive Director and Chair of the Audit and Risk Committee.
- On 23 January 2018, dorsaVi Ltd announced that CEO, Andrew Ronchi, had relocated to the US to focus on strategic relationships in the US and Europe and that Matt May had been promoted to General Manager.

Auditor's independence declaration


A copy of the auditor's independence declaration as required under section 307C of the *Corporation Act 2001* in relation to the review for the half-year is provided with this report.

DIRECTORS' REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2017

Rounding of amounts

In accordance with *ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191*, the amounts in the directors' report and in the financial report have been rounded to the nearest dollar.

Signed in accordance with a resolution of the directors:

A handwritten signature in blue ink, appearing to read 'Greg Tweedly', is written over a faint, larger version of the same signature.

Greg Tweedly
Chairman
Melbourne

Date; 15 February 2018

dorsaVi Ltd and controlled entities
AUDITOR'S INDEPENDENCE DECLARATION
TO THE DIRECTORS OF DORSAVI LTD

In relation to the independent auditor's review for the half-year ended 31 December 2017, to the best of my knowledge and belief there have been:

- (i) no contraventions of the auditor independence requirements of the *Corporations Act 2001*; and
- (ii) no contraventions of APES 110: *Code of Ethics for Professional Accountants*.

This declaration is in respect of dorsaVi Ltd and the entities it controlled during the year.



F V RUSSO
Partner
15 February 2018



PITCHER PARTNERS
Melbourne

**CONDENSED CONSOLIDATED
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2017**

	31 Dec 2017	31 Dec 2016
	\$	\$
Revenue and other income		
Sales revenue	1,949,440	1,728,724
Interest Income	69,723	49,882
Other income	219,926	175,000
	<u>2,239,089</u>	<u>1,953,606</u>
Less: Expenses		
Cost of sales	(474,186)	(453,507)
Advertising expenses	(144,108)	(100,584)
Conference expenses	(123,559)	(11,305)
Consultancy expenses	(156,630)	(148,831)
Depreciation and amortisation expenses	(251,000)	(67,000)
Device development expenditure	(17,704)	(78,699)
Employee benefits expenses	(2,275,816)	(1,956,074)
Occupancy expenses	(183,891)	(93,501)
Professional fees	(315,564)	(220,107)
Regulatory expenses	(43,680)	(59,417)
Software expenses	(119,805)	(67,575)
Travel expenses	(239,797)	(175,149)
Other expenses	(323,074)	(264,653)
	<u>(4,668,814)</u>	<u>(3,696,402)</u>
Loss before income tax benefit	(2,429,725)	(1,742,796)
Income tax benefit	457,663	479,588
Loss from continuing operations	<u>(1,972,062)</u>	<u>(1,263,208)</u>
Other comprehensive income		
Items that may be reclassified subsequently to profit and loss:		
Exchange differences on translation of foreign subsidiaries net of tax	24,584	(12,967)
Other comprehensive income for the half-year	24,584	(12,967)
Loss for the half-year	<u>(1,947,478)</u>	<u>(1,276,175)</u>

The accompanying notes form part of these condensed consolidated financial statements.

**CONDENSED CONSOLIDATED
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
(Continued)**

FOR THE HALF-YEAR ENDED 31 DECEMBER 2017

	31 Dec 2017	31 Dec 2016
	\$	\$
Loss per share from continuing operations attributable to equity holders of the parent entity:		
Basic loss per share	(1.18 cents)	(0.84 cents)
Diluted loss per share	(1.18 cents)	(0.84 cents)

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2017**

	31 Dec 2017 \$	30 June 2017 \$
Current assets		
Cash and cash equivalents	6,749,478	8,609,602
Receivables	2,178,592	2,410,615
Inventories	338,108	317,157
Other assets	315,809	146,125
Total current assets	9,581,987	11,483,499
Non-current assets		
Intangible assets	3,253,766	2,607,199
Plant and equipment	354,066	381,094
Total non-current assets	3,607,832	2,988,293
Total assets	13,189,819	14,471,792
Current liabilities		
Payables	1,288,962	930,084
Provisions	400,000	385,696
Total current liabilities	1,688,962	1,315,780
Non-current liabilities		
Provisions	32,663	30,340
Total non-current liabilities	32,663	30,340
Total liabilities	1,721,625	1,346,120
Net assets	11,468,194	13,125,672
Equity		
Share capital	38,440,518	38,440,518
Reserves	1,072,870	758,286
Accumulated losses	(28,045,194)	(26,073,132)
Total equity	11,468,194	13,125,672

**CONDENSED CONSOLIDATED
STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2017**

Consolidated Entity	Share capital	Reserves	Accumulated losses	Total Equity
	\$	\$	\$	\$
Balance as at 1 July 2016	30,709,796	93,496	(22,212,210)	8,591,082
Loss for the half-year	-	-	(1,263,208)	(1,263,208)
Exchange differences on translation of foreign operations, net of tax	-	(12,967)	-	(12,967)
Total comprehensive income for the half-year	-	(12,967)	(1,263,208)	(1,276,175)
Transactions with owners in their capacity as owners:				
Issue of shares	5,000,000	-	-	5,000,000
Share issue expenses	(292,079)	-	-	(292,079)
Employee share ownership plan	28,000	-	-	28,000
	4,735,921	-	-	4,735,921
Balance as at 31 December 2016	35,445,717	80,529	(23,475,418)	12,050,828
Balance as at 1 July 2017	38,440,518	758,286	(26,073,132)	13,125,672
Loss for the half-year	-	-	(1,972,062)	(1,972,062)
Exchange differences on translation of foreign operations, net of tax	-	24,584	-	24,584
Total comprehensive income for the half-year	-	24,584	(1,972,062)	(1,947,478)
Transactions with owners in their capacity as owners:				
Employee share ownership plan	-	290,000	-	290,000
	-	290,000	-	290,000
Balance as at 31 December 2017	38,440,518	1,072,870	(28,045,194)	11,468,194

The accompanying notes form part of these condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2017

	31 Dec 2017 \$	31 Dec 2016 \$
Cash flow from operating activities		
Receipts from customers	2,341,336	1,986,835
Payments to suppliers and employees	(4,236,649)	(3,952,998)
Grants received	77,224	-
Interest received	69,723	49,882
Income tax refunded	871,112	678,466
Net cash used in operating activities	(877,254)	(1,237,815)
Cash flow from investing activities		
Payment for plant and equipment	(12,303)	(39,043)
Payment for intangibles	(970,567)	(761,614)
Net cash used in investing activities	(982,870)	(800,657)
Cash flow from financing activities		
Proceeds from share issue	-	5,000,000
Cost of raising capital	-	(292,079)
Proceeds from employee share ownership plan	-	28,000
Net cash provided by financing activities	-	4,735,921
Net (decrease)/increase in cash and cash equivalents	(1,860,124)	2,697,449
Cash and cash equivalents at beginning of the half-year	8,609,602	6,029,185
Cash and cash equivalents at end of the half-year	6,749,478	8,726,634

The accompanying notes form part of these condensed consolidated financial statements.

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

NOTE 1: BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL REPORT

This condensed consolidated half-year financial report does not include all the notes of the type usually included in an annual financial report.

It is recommended that this half-year financial report be read in conjunction with the annual financial report for the year ended 30 June 2017 and any public announcements made by dorsaVi Ltd during the half-year in accordance with any continuous disclosure obligations arising under the *Corporations Act 2001*.

This condensed half-year financial report covers dorsaVi Ltd and controlled entities as a consolidated entity. dorsaVi Ltd is a company limited by shares, incorporated and domiciled in Australia. The address of dorsaVi Ltd's principal place of business is Level 1, 120 Jolimont Road, Melbourne East, Victoria. dorsaVi Ltd is a for-profit entity for the purpose of preparing the financial statements.

The half-year financial report was authorised for issue by the directors as at the date of the directors' report.

(a) Basis of preparation

This condensed consolidated half-year financial report has been prepared in accordance with Australian Accounting Standard AASB 134 *Interim Financial Reporting* as appropriate for for-profit entities and the *Corporations Act 2001*. Compliance with AASB 134, as appropriate for for-profit entities, ensures compliance with International Financial Reporting Standard IAS 34 *Interim Financial Reporting*.

The half-year financial report has been prepared under the historical cost convention, as modified by revaluations to fair value for certain classes of assets as described in the accounting policies.

The accounting policies applied in this half-year financial report are consistent with those of the annual financial report for the year ended 30 June 2017 and the corresponding half-year except as described in note 1(b).

(b) Summary of the significant accounting policies

The AASB has issued a number of new and amended Accounting Standards and Interpretations that have mandatory application dates for future reporting periods, some of which are relevant to the Group. The Group has decided not to early adopt any of these new and amended pronouncements. The Group's assessment of the new and amended pronouncements that are relevant to the Group but applicable in future reporting periods is set out below.

(c) Accounting Standards Issued but not yet Effective

- AASB 9: Financial Instruments (December 2014), AASB 2014-7: Amendments to Australian Accounting Standards arising from AASB 9 (December 2014), AASB 2014-8: Amendments to Australian Accounting Standards arising from AASB 9 (December 2014) – Application of AASB 9 (December 2009) and AASB 9 (December 2010) (applicable for annual reporting periods commencing on or after 1 January 2018).

These Standards will replace AASB 139: Financial Instruments: Recognition and Measurement. Key changes that may affect the Group on application of AASB 9 and associated amending Standards include:

- Simplifying the general classifications of financial assets into those carried at amortised cost and those carried at fair value;

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

- Permitting entities to irrevocably elect on initial recognition to present gains and losses on an equity instrument that is not held for trading in other comprehensive income (OCI);
- Simplifying the requirements for embedded derivatives, including removing the requirements to separate and fair value embedded derivatives for financial assets carried at amortised cost;
- Introducing a new model for hedge accounting that permits greater flexibility in the ability to hedge risk, particularly with respect to non-financial items; and
- Requiring impairment of financial assets carried at amortised cost to be based on an expected loss approach.

Although the directors anticipate that the adoption of AASB 9 may have an impact on the Group's financial instruments, it is impracticable at this stage to provide a reasonable estimate of such impact.

- AASB 15: Revenue from Contracts with Customers, AASB 2014-5: Amendments to Australian Accounting Standards arising from AASB 15, AASB 2015-8: Amendments to Australian Accounting Standards – Effective Date of AASB 15 and AASB 2016-3: Amendments to Australian Accounting Standards – Clarifications to AASB 15 and AASB 2016-7 (applicable for annual reporting periods commencing on or after 1 January 2018).

AASB 15 will provide (except in relation to some specific exceptions, such as lease contracts and insurance contracts) a single source of accounting requirements for all contracts with customers, thereby replacing all current accounting pronouncements on revenue.

These Standards provide a revised principle for recognising and measuring revenue. Under AASB 15, revenue is recognised in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the provider of the goods or services expects to be entitled. To give effect to this principle, AASB 15 requires the adoption of the following 5-step model:

- Identify the contract(s) with a customer;
- Identify the performance obligations under the contract(s);
- Determine the transaction price;
- Allocate the transaction price to the performance obligations under the contract(s); and
- Recognise revenue when (or as) the entity satisfies the performance obligations.

AASB 15 also provides additional guidance to assist entities in applying the revised principle to licences of intellectual property, warranties, rights of return, principal/agent considerations and options for additional goods and services.

Although the directors anticipate that the adoption of AASB 15 may have an impact on the Group's reported revenue, it is impracticable at this stage to provide a reasonable estimate of such impact.

- AASB 16: Leases (applicable for annual reporting periods commencing on or after 1 January 2019).

AASB 16 will replace AASB 117: Leases and introduces a single lessee accounting model that will require a lessee to recognise right-of-use assets and lease liabilities for all leases with a term of more than 12 months, unless the underlying asset is of low value. Right-of-use assets are initially measured at their cost and lease liabilities are initially measured on a present value basis. Subsequent to initial recognition:

- Right-of-use assets are accounted for on a similar basis to non-financial assets, whereby the right-of-use asset is accounted for in accordance with a cost model unless the underlying asset is accounted for on a revaluation basis, in which case if the underlying asset is:
 - Investment property, the lessee applies the fair value model in AASB 140: Investment Property to the right-of-use asset; or

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

- Property, plant or equipment, the lessee can elect to apply the revaluation model in AASB 116: Property, Plant and Equipment to all of the right-of-use assets that relate to that class of property, plant and equipment; and
- Lease liabilities are accounted for on a similar basis as other financial liabilities, whereby interest expense is recognised in respect of the liability and the carrying amount of the liability is reduced to reflect lease payments made.

AASB 16 substantially carries forward the lessor accounting requirements in AASB 117. Accordingly, under AASB 16 a lessor would continue to classify its leases as operating leases or finance leases subject to whether the lease transfers to the lessee substantially all of the risks and rewards incidental to ownership of the underlying asset and would account for each type of lease in a manner consistent with the current approach under AASB 117.

Although the directors anticipate that the adoption of AASB 16 may have an impact on the Group's accounting for its operating leases, it is impracticable at this stage to provide a reasonable estimate of such impact.

- AASB 2016-2: Amendments to Australian Accounting Standards – Disclosure Initiative: Amendments to AASB 107 (applicable for annual reporting periods commencing on or after 1 January 2017).

This Amending Standard amends AASB 107: Statement of Cash Flows to require entities to provide disclosures that enable users of financial statements to evaluate changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes. To the extent necessary to satisfy this objective, entities will be required to disclose the following changes in liabilities arising from financing activities:

- Changes from financing cash flows;
- Changes arising from obtaining or losing control of subsidiaries or other businesses;
- The effect of changes in foreign exchange rates;
- Changes in fair values; and
- Other changes.

This Standard is not expected to significantly impact the Group's financial statements.

- AASB 2016-5: Amendments to Australian Accounting Standards – Classification and Measurement of Share-based Payment Transactions (applicable for annual reporting periods commencing on or after 1 January 2018).

This Amending Standard amends AASB 2: Share-based Payment to address:

- The accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments;
- The classification of share-based payment transactions with a net settlement feature for withholding tax obligations; and
- The accounting for a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled.

This Standard is not expected to significantly impact the Group's financial statements.

- AASB Interpretation 22: Foreign Currency Transactions and Advance Consideration (applicable for annual reporting periods commencing on or after 1 January 2018).

Interpretation 22 clarifies that, in applying AASB 121: The Effects of Changes in Foreign Exchange Rates, the date of the transaction for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income (or part of it) is the date on which an entity initially recognises the non-monetary asset or non-monetary liability arising from the payment or receipt of advance consideration. Accordingly, if there are multiple payments or receipts in advance, the entity is required to determine a date of the transaction for each payment or receipt of advance consideration.

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

This Interpretation is not expected to significantly impact the Group's financial statements.

- AASB Interpretation 23: Uncertainty over Income Tax Treatments (applicable for annual reporting periods commencing on or after 1 January 2019).

Interpretation 23 clarifies how to apply the recognition and measurement requirements in AASB 112: Income Taxes when there is uncertainty over income tax treatments. To this end, Interpretation 23 requires:

- An entity to consider whether each uncertain tax treatment should be considered separately or together with one or more other uncertain tax treatments based on which approach better predicts the resolution of the uncertainty;
- In assessing whether and how an uncertain tax treatment affects the determination of taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates, assume that the taxation authority will examine amounts it has a right to examine and have full knowledge of all related information when making those examinations;
- If the entity concludes that it is probable that the taxation authority will accept the uncertain tax treatment, the entity will determine current tax and deferred tax consistently with the treatment used or planned to be used in its income tax filings;
- If the entity concludes that it is not probable that the taxation authority will accept an uncertain tax treatment, the entity reflects the effect of uncertainty in the determination of current tax and deferred tax, based on either the 'most likely' amount or the 'probability-weighted' amount of tax (depending on which method the entity expects to better predict the resolution of the uncertainty); and
- An entity to reassess a judgement or estimate required under Interpretation 23 if the facts and circumstances on which the judgement or estimate was based change or as a result of new information that affects the judgement or estimate.

This Interpretation is not expected to significantly impact the Group's financial statements.

(d) Fair value measurement

The carrying amounts of the Company's financial instruments, valued at amortised cost (including receivables and payables), are reasonable approximations of the fair value of these instruments.

(e) Comparatives

Where necessary, comparative information has been reclassified and repositioned for consistency with current year disclosures.

(f) Rounding amounts

In accordance with ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, the amounts in the directors' report and in the financial report have been rounded to the nearest dollar.

NOTE 2: SEGMENT INFORMATION

(a) Description of segments

Management differentiates operating segments based on geographical areas and regulatory environments. The type of products and services from which each reportable segment derives its revenue is considered the same.

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

NOTE 2: SEGMENT INFORMATION (cont.)

The operating segments have been identified based on internal reports reviewed by the consolidated entity's chief operating decision makers in order to allocate resources to the segment and assess its performance

dorsaVi Ltd and controlled entities are comprised of the following reportable segments:

- Segment 1: Australia
- Segment 2: Europe
- Segment 3: United States of America

(b) Segment information

The consolidated entity's chief operating decision maker's use segment revenue and segment results to assess the financial performance of each operating segment.

Amounts for segment information are measured in the same way in the financial statements. They include items directly attributable to the segment and those that can reasonably be allocated to the segment based on the operations of the segment. There have been no inter-segment revenue or expenses during the period.

Segment information is reconciled to financial statements and underlying profit disclosures notes as following:

Half-year – 31 Dec 2017	Australia	Europe	USA	Total
	\$	\$	\$	\$
Segment revenue				
Total segment revenue	1,132,687	414,290	692,112	2,239,089
Segment revenue from external source	1,132,687	414,290	692,112	2,239,089
Segment result				
Total segment result	(720,658)	(493,564)	(757,840)	(1,972,062)
Segment result from external source	(720,658)	(493,564)	(757,840)	(1,972,062)
Items included within the segment result:				
Foreign exchange loss	(23,705)	-	-	(23,705)
Grant income	219,926	-	-	219,926
Interest income	69,721	2	-	69,723
Depreciation and amortisation expense	(251,000)	-	-	(251,000)
Income tax benefit	457,650	13	-	457,663
Total segment assets	23,041,487	885,417	1,272,879	25,199,783
Elimination				(12,009,964)
Consolidated segment assets				13,189,819
Total assets include:				
Additions to non-current assets	870,539	-	-	870,539
Total segment liabilities	(2,103,558)	(3,812,868)	(7,815,163)	(13,731,589)
Elimination				12,009,964
Consolidated segment liabilities				(1,721,625)

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

NOTE 2: SEGMENT INFORMATION (cont.)

Half-year – 31 Dec 2016

	Australia \$	Europe \$	USA \$	Total \$
Segment revenue				
Total segment revenue	1,123,894	312,010	517,702	1,953,606
Segment revenue from external source				
	1,123,894	312,010	517,702	1,953,606
Segment result				
Total segment result	(939,800)	(91,016)	(232,392)	(1,263,208)
Segment result from external source				
	(939,800)	(91,016)	(232,392)	(1,263,208)
Items included within the segment result:				
Foreign exchange gain	(49,549)	-	-	(49,549)
Grant income	175,000	-	-	175,000
Interest income	49,874	8	-	49,882
Depreciation and amortisation expense	(67,000)	-	-	(67,000)
Income tax benefit	479,588	-	-	479,588
Total segment assets	19,692,649	916,806	602,719	21,212,174
Elimination				(8,128,976)
Consolidated segment assets				13,083,198
Total assets include:				
Additions to non-current assets	818,512	-	-	818,512
Total segment liabilities	(750,289)	(2,920,030)	(5,491,027)	(9,161,346)
Elimination				8,128,976
Consolidated segment liabilities				(1,032,370)

(c) Major customers

There were no customers who accounted for a revenue value greater than 10% of the Group's revenue.

NOTE 3: PLANT AND EQUIPMENT

Acquisitions and disposals

During the six months ended 31 December 2017 the Group acquired assets with a cost of \$24,972 (31 December 2016: \$56,898) which included \$12,303 purchased externally (31 December 2016: \$39,043) and \$12,669 of devices transferred from inventories (31 December 2016: \$17,855).

No assets were disposed of during the period ended 31 December 2017.

NOTE 4: INTANGIBLE ASSETS

	31 Dec 2017 \$	30 June 2017 \$
Patents, at cost	839,251	745,402
Less accumulated amortisation	(124,462)	(105,462)
Development expenditure, at cost	2,662,574	1,910,856
Less accumulated amortisation	(235,707)	(55,707)
Goodwill, at cost	112,110	112,110
	<u>3,253,766</u>	<u>2,607,199</u>

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

NOTE 4: INTANGIBLE ASSETS (Cont.)

(a) Reconciliation

Reconciliation of the carrying amounts of intangible assets at the beginning and end of the half-year ending 31 December 2017 are provided below:

	Goodwill	Patents	Intangibles	Total
	\$	\$	\$	\$
Opening balance	112,110	639,940	1,855,149	2,607,199
Additions	-	93,849	751,718	845,567
Amortisation expense	-	(19,000)	(180,000)	(199,000)
Closing balance	112,110	714,789	2,426,867	3,253,766

NOTE 5: CONTRIBUTED CAPITAL

During the half-year ended 31 December 2017, the company issued 571,113 ordinary shares (31 December 2016: nil) through the employee share ownership plan (ESOP).

During the half-year ended 31 December 2016, the company issued 10,869,565 shares, at \$0.46 each, through a placement of shares with sophisticated and institutional investors.

(a) Movements in shares on issue

	Parent Equity		Parent Equity	
	Half-year		Half-year	
	31 Dec 2017		31 Dec 2016	
	No of Shares	\$	No of Shares	\$
Beginning of the half-year	167,305,859	38,440,518	149,914,616	30,709,796
Movement during the half-year				
- Employee share scheme	571,113	-	-	-
- Employee loan share receipts	-	-	-	28,000
- Shares issued in capital raising	-	-	10,869,565	5,000,000
- Cost of raising capital	-	-	-	(292,079)
End of the half-year	167,876,972	38,440,518	160,784,181	35,445,717

(b) Employee Share Ownership Plan (ESOP)

As disclosed in previous Annual Reports, the Board has established an ESOP. This plan was established by the Company to facilitate the acquisition of shares and options by those employed, or otherwise engaged by, or holding a position of office in, dorsaVi Ltd.

(i) Loan Shares

Between 30 June 2017 and 31 December 2017, no loan shares were issued.

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

NOTE 5: CONTRIBUTED CAPITAL (cont.)

(ii) Options over shares

dorsaVi Ltd may grant options under the ESOP. dorsaVi Ltd did not grant any options to purchase ordinary shares in the Company during the six months ended 31 December 2017 (December 2016: nil).

(iii) Performance rights

dorsaVi Ltd may grant performance rights under the ESOP. dorsaVi Ltd did not grant any performance rights during the six months ended 31 December 2017 (December 2016: 900,000). Performance rights are subject to performance and vesting conditions and do not vest into shares unless these conditions are met. During the six months ended 31 December 2017, 571,113 ordinary shares were issued on the vesting of performance rights previously granted (December 2016: nil).

Details of employee loan shares, options and performance rights granted are provided below:

Half-year ended 31 December 2017

Grant date	Expiry date	Exercise price	Balance at 1/07/2017	Exercised during period	Cancelled/expired during period	Balance at half year-end	Exercisable at half year-end
3/07/2014	3/07/2019	\$0.46	250,000	-	-	250,000	250,000
2/09/2014	1/09/2019	\$0.40	100,000	-	-	100,000	100,000
5/11/2014	5/11/2019	\$0.40	20,000	-	-	20,000	20,000
25/02/2015	25/02/2020	\$0.36	80,000	-	-	80,000	80,000
17/08/2015	17/08/2020	\$0.26	500,000	-	-	500,000	500,000
24/03/2016	24/03/2021	\$0.40	200,000	-	-	200,000	100,000
29/11/2016	-	-	150,000	(75,000)	(75,000)	-	-
29/11/2016	1/10/2018	-	150,000	-	-	150,000	-
29/11/2016	1/10/2019	-	150,000	-	-	150,000	-
29/11/2016	29/11/2019	-	450,000	-	-	450,000	-
15/05/2017	15/05/2022	\$0.33	550,000	-	-	550,000	550,000
15/05/2017	1/10/2022	\$0.33	133,333	-	(78,333)	55,000	55,000
15/05/2017	1/10/2023	\$0.33	133,333	-	-	133,333	-
15/05/2017	1/10/2024	\$0.33	133,334	-	-	133,334	-
15/05/2017	1/07/2024	\$0.33	350,000	-	-	350,000	-
15/05/2017	-	-	79,000	(54,050)	(24,950)	-	-
15/05/2017	1/10/2023	-	39,000	-	-	39,000	-
15/05/2017	1/10/2024	-	39,000	-	-	39,000	-
15/05/2017	1/07/2024	-	117,000	-	-	117,000	-
5/06/2017	-	-	250,000	(250,000)	-	-	-
5/06/2017	-	-	350,000	(192,063)	(157,937)	-	-
5/06/2017	1/10/2018	-	350,000	-	-	350,000	-
5/06/2017	1/10/2019	-	350,000	-	-	350,000	-
5/06/2017	1/07/2019	-	775,000	-	-	775,000	-
5/06/2017	1/01/2018	-	83,334	-	(52,084)	31,250	-
5/06/2017	1/01/2019	-	83,334	-	-	83,334	-
5/06/2017	1/01/2020	-	333,332	-	-	333,332	-
Total			6,199,000	(571,113)	(388,304)	5,239,583	1,655,000

NOTES TO THE CONDENSED CONSOLIDATED HALF-YEAR FINANCIAL STATEMENTS

NOTE 5: CONTRIBUTED CAPITAL (cont.)

Half-year ended 31 December 2016

Grant date	Expiry date	Exercise price	Balance at 1/07/2016	Granted during period	Exercised during period	Cancelled/ expired during period	Balance at half year-end	Exercisable at half year-end
3/07/2014	3/07/2019	\$0.46	250,000	-	-	-	250,000	250,000
2/09/2014	1/09/2019	\$0.40	100,000	-	-	-	100,000	75,000
31/10/2014	30/10/2019	\$0.40	900,000	-	-	(900,000)	-	-
5/11/2014	5/11/2019	\$0.40	20,000	-	-	-	20,000	20,000
25/02/2015	25/02/2020	\$0.36	80,000	-	-	-	80,000	80,000
17/08/2015	17/08/2020	\$0.26	500,000	-	-	-	500,000	500,000
30/09/2015	30/09/2020	\$0.28	250,000	-	-	-	250,000	250,000
30/09/2015	30/09/2021	\$0.28	250,000	-	-	-	250,000	250,000
30/09/2015	30/09/2022	\$0.28	250,000	-	-	-	250,000	-
11/12/2015	11/12/2016	\$0.38	277,778	-	-	(277,778)	-	-
24/03/2016	24/03/2021	\$0.40	200,000	-	-	-	200,000	100,000
8/06/2016	8/06/2021	\$0.34	50,000	-	-	-	50,000	14,583
29/11/2016	1/10/2017	-	-	150,000	-	-	150,000	-
29/11/2016	1/10/2018	-	-	150,000	-	-	150,000	-
29/11/2016	1/10/2019	-	-	150,000	-	-	150,000	-
29/11/2016	29/11/2019	-	-	450,000	-	-	450,000	-
Total			3,127,778	900,000	-	(1,177,778)	2,850,000	1,539,583

NOTE 6: DIVIDENDS

There were no dividends paid during the period.

NOTE 7: SUBSEQUENT EVENTS

On 23 January 2018, dorsaVi Ltd announced that CEO, Andrew Ronchi, had relocated to the US to focus on strategic relationships in the US and Europe and that Matt May had been promoted to General Manager.

NOTE 8: CONTINGENT LIABILITIES


There have been no changes in contingent liabilities since 30 June 2017.

DIRECTORS' DECLARATION

The directors declare that:

1. In the directors' opinion, the financial statements and notes thereto, as set out on pages 7 to 20, are in accordance with the *Corporations Act 2001*, including:
 - (a) complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*; and
 - (b) giving a true and fair view of the financial position of the consolidated entity as at 31 December 2017 and of its performance for the half-year ended on that date.
2. In the directors' opinion there are reasonable grounds, at the date of this declaration, to believe that dorsaVi Ltd will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Greg Tweedly
Chairman
Melbourne
Date: 15 February 2018

**DORSAVI LTD
ABN 15 129 742 408
AND CONTROLLED ENTITIES**

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
DORSAVI LTD**

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of dorsaVi Ltd 'the Company' and its controlled entities 'the Group', which comprises the condensed consolidated statement of financial position as at 31 December 2017, the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of dorsaVi Ltd and controlled entities, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of dorsaVi Ltd, would be in the same terms if given to the directors as at the time of this auditor's report.

**DORSAVI LTD
ABN 15 129 742 408
AND CONTROLLED ENTITIES**

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
DORSAVI LTD**


Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of dorsaVi Ltd and controlled entities is not in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.



F V RUSSO
Partner
15 February 2018



PITCHER PARTNERS
Melbourne